183 related articles for article (PubMed ID: 34732839)
1. Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations.
Stachtea X; Loughrey MB; Salvucci M; Lindner AU; Cho S; McDonough E; Sood A; Graf J; Santamaria-Pang A; Corwin A; Laurent-Puig P; Dasgupta S; Shia J; Owens JR; Abate S; Van Schaeybroeck S; Lawler M; Prehn JHM; Ginty F; Longley DB
Mod Pathol; 2022 Apr; 35(4):564-576. PubMed ID: 34732839
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
Front Immunol; 2019; 10():2936. PubMed ID: 31921188
[TBL] [Abstract][Full Text] [Related]
3. SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.
Chew A; Salama P; Robbshaw A; Klopcic B; Zeps N; Platell C; Lawrance IC
PLoS One; 2011; 6(7):e22047. PubMed ID: 21818290
[TBL] [Abstract][Full Text] [Related]
4. Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T; Hazama S; Suzuki N; Yoshida S; Tomochika S; Nakagami Y; Matsui H; Shindo Y; Kanekiyo S; Tokumitsu Y; Iida M; Tsunedomi R; Takeda S; Yoshino S; Okayama N; Suehiro Y; Yamasaki T; Fujita T; Kawakami Y; Ueno T; Nagano H
Br J Cancer; 2019 Oct; 121(8):659-665. PubMed ID: 31488881
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
6. Associations of different immune checkpoints-expressing CD4
Al-Mterin MA; Murshed K; Alsalman A; Abu-Dayeh A; Elkord E
BMC Cancer; 2022 Jun; 22(1):601. PubMed ID: 35655158
[TBL] [Abstract][Full Text] [Related]
7. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
8. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
[TBL] [Abstract][Full Text] [Related]
9. A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer.
Chen Y; Yuan R; Wu X; He X; Zeng Y; Fan X; Wang L; Wang J; Lan P; Wu X
Ann Surg Oncol; 2016 Mar; 23(3):826-32. PubMed ID: 26581202
[TBL] [Abstract][Full Text] [Related]
10. Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer.
Bergsland CH; Jeanmougin M; Moosavi SH; Svindland A; Bruun J; Nesbakken A; Sveen A; Lothe RA
Mod Pathol; 2022 Sep; 35(9):1236-1246. PubMed ID: 35484226
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C
Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314
[TBL] [Abstract][Full Text] [Related]
12. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
13. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
[TBL] [Abstract][Full Text] [Related]
15. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer.
Waniczek D; Lorenc Z; Śnietura M; Wesecki M; Kopec A; Muc-Wierzgoń M
Arch Immunol Ther Exp (Warsz); 2017 Oct; 65(5):445-454. PubMed ID: 28343267
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer.
Kim S; Kang SI; Kim S; Kim JH
J Surg Res; 2021 Nov; 267():391-396. PubMed ID: 34218138
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
19. Poor Prognosis in Patients With Stage III Colorectal Cancer Receiving Adjuvant FOLFOX/CAPOX Therapy Is Predicted by the Presence of Many Poorly Differentiated Clusters.
Yoshimatsu K; Kono T; Satake M; Ito Y; Shiozawa S; Tanaka H; Higashida M; Okada T; Endo S; Fujiwara Y; Ueno T
Anticancer Res; 2023 Jul; 43(7):3235-3240. PubMed ID: 37352004
[TBL] [Abstract][Full Text] [Related]
20. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
